Genmab A/S ADS

Analyst Ratings Synthesis

Supplied consensus is Buy across 18 analysts, with a mean 12-month target of $44.10; the low and high targets are not available, so the target range and dispersion cannot be quantified. At the October 29 close of $56.49, the shares were above that mean. The evidence does not name the most- or least-bullish analyst, provide a firm-by-firm target distribution, or identify any rating or target revisions during the week. Consequently, the measurable consensus is broadly positive, while the available price-target benchmark sits below the market price. The substantive evidence-driven divide is between the potential value of positive late-stage cancer-trial results and the uncertainty of converting those readouts into approved, launched products; no analyst commentary in the supplied material quantifies that debate.

• Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
• Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%
• Genmab's Petosemtamab Combination Improves Survival In Phase 3 Head And Neck Cancer Trial; Stock Up
• Genmab Reaches Analyst Target Price
• Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy